Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

QUAdruple Therapy With RASi, Empagliflozin, Finerenone, and Mazdutide in Type 2 Diabetes and Early Treatment of Nephropathy(QUARTET-DKD)

NCT07775846 is registered in ClinicalTrials.gov with Huijie Zhang as lead sponsor.

NCT NCT07775846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07775846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
QUAdruple Therapy With RASi, Empagliflozin, Finerenone, and Mazdutide in Type 2 Diabetes and Early Treatment of Nephropathy(QUARTET-DKD)
Lead sponsor
Huijie Zhang
Phase
Phase 4
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
June 30, 2029
Enrollment
820 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetic kidney disease